Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 9/20 | 0.68 |
| ▸ | IKBKE | Q14164 | 14/20 | 0.66 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032682 | 0.89 | IKBKE (0.67) | PLK1IKBKETBK1 | |
| SCHEMBL4034533 | 0.87 | IKBKE (0.67) | PLK1IKBKETBK1 | |
| SCHEMBL4032804 | 0.83 | IKBKE (0.80) | PLK1IKBKETBK1 | |
| Gsk-204925A SCHEMBL4367870 | 0.81 | PLK1 (1.00) | PLK1 | |
| SCHEMBL4032568 | 0.80 | IKBKE (0.78) | PLK1IKBKETBK1 | |
| SCHEMBL4035301 | 0.80 | IKBKE (0.70) | PLK1IKBKETBK1 | |
| SCHEMBL4036540 | 0.80 | PLK1 (0.68) | PLK1IKBKETBK1 | |
| SCHEMBL4032882 | 0.80 | IKBKE (0.69) | PLK1IKBKETBK1 | |
| SCHEMBL4038453 | 0.79 | IKBKE (1.00) | PLK1IKBKETBK1 | |
| SCHEMBL4035225 | 0.78 | IKBKE (1.00) | PLK1IKBKETBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720864-B1 | BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON IKK3 | GLAXO GROUP LTD (GB) | 2009-05-06 | — | — | EP | claimed |
| EP-2259787-B1 | IKKI INHIBITOR THERAPIES AND SCREENING METHODS, AND RELATED IKKI DIAGNOSTICS | UNIV MICHIGAN (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-1720864-B1 | BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON IKK3 | GLAXO GROUP LTD (GB) | 2009-05-06 | — | — | EP | disclosed |
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | IKBKE, IKBKB, TBK1 | PLK1 1088/4885IKBKE 1/4885TBK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.